PRAMIPEXOLE DIHYDROCHLORIDE — pramipexole dihydrochloride tablet
A-S Medication Solutions
Pramipexole dihydrochloride tablets are indicated for the treatment of Parkinson’s disease.
Pramipexole dihydrochloride tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Pramipexole dihydrochloride tablets are taken orally, with or without food.If a significant interruption in therapy with pramipexole dihydrochloride tablets has occurred, re-titration of therapy may be warranted.
In all clinical studies, dosage was initiated at a subtherapeutic level to avoid intolerable adverse effects and orthostatic hypotension. Pramipexole dihydrochloride tablets should be titrated gradually in all patients. The dose should be increased to achieve a maximum therapeutic effect, balanced against the principal side effects of dyskinesia, hallucinations, somnolence, and dry mouth.
Dosing in Patients with Normal Renal Function
Initial Treatment Doses should be increased gradually from a starting dose of 0.375 mg/day given in three divided doses and should not be increased more frequently than every 5 to 7 days. A suggested ascending dosage schedule that was used in clinical studies is shown in Table 1:
|Week||Dosage (mg)||Total Daily Dose (mg)|
|1||0.125 three times a day||0.375|
|2||0.25 three times a day||0.75|
|3||0.5 three times a day||1.5|
|4||0.75 three times a day||2.25|
|5||1 three times a day||3|
|6||1.25 three times a day||3.75|
|7||1.5 three times a day||4.5|
Pramipexole dihydrochloride tablets were effective and well tolerated over a dosage range of 1.5 to 4.5 mg/day administered in equally divided doses three times per day with or without concomitant levodopa (approximately 800 mg/day).
In a fixed-dose study in early Parkinson’s disease patients, doses of 3 mg, 4.5 mg, and 6 mg per day of pramipexole dihydrochloride tablets were not shown to provide any significant benefit beyond that achieved at a daily dose of 1.5 mg/day. However, in the same fixed-dose study, the following adverse events were dose related: postural hypotension, nausea, constipation, somnolence, and amnesia. The frequency of these events was generally 2-fold greater than placebo for pramipexole doses greater than 3 mg/day. The incidence of somnolence reported with pramipexole at a dose of 1.5 mg/day was comparable to placebo.
When pramipexole dihydrochloride tablets are used in combination with levodopa, a reduction of the levodopa dosage should be considered. In a controlled study in advanced Parkinson’s disease, the dosage of levodopa was reduced by an average of 27% from baseline.
Dosing in Patients with Renal ImpairmentThe recommended dosing of pramipexole dihydrochloride tablets in Parkinson’s disease patients with renal impairment is provided in Table 2.
|Renal Status||Starting Dose (mg)||Maximum Dose (mg)|
|Normal to mild impairment (creatinine Cl >50 mL/min)||0.125 three times a day||1.5 three times a day|
|Moderate impairment (creatinine Cl = 30 to 50 mL/min)||0.125 twice a day||0.75 three times a day|
|Severe impairment (creatinine Cl = 15 to <30 mL/min)||0.125 once a day||1.5 once a day|
|Very severe impairment (creatinine Cl <15 mL/min and hemodialysis patients)||The use of pramipexole dihydrochloride tablets has not been adequately studied in this group of patients.|
Discontinuation of TreatmentPramipexole dihydrochloride tablets may be tapered off at a rate of 0.75 mg per day until the daily dose has been reduced to 0.75 mg. Thereafter, the dose may be reduced by 0.375 mg per day [see Warnings and Precautions (5.10) ].
The recommended starting dose of pramipexole dihydrochloride tablets is 0.125 mg taken once daily 2 to 3 hours before bedtime. For patients requiring additional symptomatic relief, the dose may be increased every 4 to 7 days (Table 3). Although the dose of pramipexole dihydrochloride tablets was increased to 0.75 mg in some patients during long-term open-label treatment, there is no evidence that the 0.75 mg dose provides additional benefit beyond the 0.5 mg dose.
Table 3 Ascending Dosage Schedule of Pramipexole Dihydrochloride tablets for RLS
|Titration Step||Duration||Dose (mg) to be taken once daily, 2 to 3 hours before bedtime|
|1||4 to 7 days||0.125|
|2*||4 to 7 days||0.25|
|3*||4 to 7 days||0.5|
Dosing in Patients with Renal Impairment
The duration between titration steps should be increased to 14 days in RLS patients with moderate and severe renal impairment (creatinine clearance 20 to 60 mL/min) [ see Clinical Pharmacology (12.3)].
Discontinuation of Treatment
In clinical trials of patients being treated for RLS with doses up to 0.75 mg once daily, pramipexole dihydrochloride tablets were discontinued without a taper. In a 26 week placebo-controlled clinical trial, patients reported a worsening of RLS symptom severity as compared to their untreated baseline when pramipexole dihydrochloride tablets treatment was suddenly withdrawn [see Warnings and Precautions (5.10)].
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.